MYL News and Press, Mylan N.V. From 06/25/20

Reuters is reporting biopharma giant Sanofi (NASDAQ: SNY) will discuss job cuts with staff representatives tomorrow and Monday that could reduce its headcount by up to 1,000 people. The possible reorganization is part of plans announced in December to eliminate $2.24 billion in spending ...

For Biogen (NASDAQ: BIIB) and its investors, the next 12 months may result in great opportunity or dashed hopes. A lot is riding on a patent appeal concerning Biogen's blockbuster multiple sclerosis (MS) drug, Tecfidera, and a U.S. Food and Drug Administration decision on the company's poten...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

As COVID-19, the illness caused by the novel coronavirus, spread throughout the world, researchers have been testing both old and new treatments in attempts to find a cure. One that has drawn particular attention is hydroxychloroquine, a common malaria drug. Image source: Getty Images. Hydroxy...

Biogen 's (NASDAQ: BIIB) Tecfidera is one of the world's best-selling multiple sclerosis drugs, and on Thursday, a judge in the Northern District of West Virginia ruled that a key patent on it is invalid. The decision means that Mylan (NASDAQ: MYL) , the plaintiff in the suit, will be able...

HERTFORDSHIRE, England and PITTSBURGH , June 18, 2020 /PRNewswire/ -- Mylan N.V.  (NASDAQ: MYL) today announced that the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera ® patent, U.S. Patent No. 8,399,514, for lack of writ...

Biogen ( BIIB -6.4% ) is down out the gate after a West Virginia judge found that generic drugmaker Mylan ( MYL +6.1% ) demonstrated Biogen's U.S. patent '514 for multiple sclerosis med Tecfidera (dimethyl fumarate) was "invalid for lack of written description." More news on: Biogen In...

Upjohn, a wholly-owned subsidiary of Newco, Pfizer (NYSE: PFE ) and Mylan N.V. (NASDAQ: MYL ) has priced a private offering of $7.45B aggregate principal amount of Newco’s senior notes and a private offering of €3.60B aggregate principal amount of Finco’s senior n...

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are both multinational pharmaceutical heavyweights, complete with massive development pipelines, numerous subsidiaries, and consistently profitable operations. With nearly identical market caps in the $200 billion range, Merck and Pfizer appear to...

Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq: MYL) today announced the pricing of a pri...